To further explore the possible mechanisms of how PIEZO1 may contribute to worse clinical responses in HR-negative breast cancer, we investigated whether there is an association between PIEZO1 and the anti-cancer immune response in HR-negative breast cancer. The gene discussed is PIEZO1; the disease is cancer.